The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Phase II Clinical Trial
3.1.1. Study Design and Enrollment
3.1.2. Patient Characteristics
3.2. Toxicity
3.3. Proliferation by Ki-67 Index
3.4. Histological Response Using GOG-211 Criteria
3.5. Biomarkers of Response by IHC
3.6. Transcriptional Analysis
3.7. Laboratory and Physical Evaluations
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A. Data Supplemental to the Main Text
Histological Response Features | Values | Rules | Score |
---|---|---|---|
Histologic grade | 1, partial; 0, none; 9, uncertain | Partial response, any decrease; Complete response, NA; No response, stays flat or increases | 1, 2, 3 |
Nuclear grade | 1, partial; 0, none; 9, uncertain | Partial response, any decrease; Complete response, NA; No response, stays flat or increases | 1, 2, 3 |
Nucleoli | 1, partial; 0, none; 9, uncertain | Partial response, present to absent; Response, present to NA; No response, present to present | Absent; Present |
Nuclear stratification | 1, partial; 0, none; 9, uncertain | Partial response, decrease; Complete response, NA; No response, stays flat or increases | Absent, 0; Mild, 1; Moderate, 2; Marked, 3 |
Eosinophilic metaplasia | 1, partial; 0, none; 9, uncertain | Some response, neg to pos; No response, neg to neg or pos to neg; No tumor content, NA | Negative, <10%Positive, ≥10% |
Squamous metaplasia | 1, partial; 0, none; 9, uncertain | Some response, neg to pos; No response, neg to neg or pos to neg; No tumor content, NA | Negative, <10%Positive, ≥10% |
Mucinous metaplasia | 1, partial; 0, none; 9, uncertain | Some response, neg to pos; No response, neg to neg or pos to neg; No tumor content, NA | Negative, <10%Positive, ≥10% |
Secretion | 1, partial; 0, none; 9, uncertain | Luminal/Subnuclear/Apical, increased secretion; Response, absent to any secretion; No response, any secretion to absent | Luminal, Subnuclear, Apical, Absent |
Mitotic index | 1, partial; 0, none; 9, uncertain | Some response, decrease; Complete response, NA; Partial response, tumor but no mitosis; No response, non-decreasing | Mitosis per HPF (average of 3 fields) |
Gland cellularity | 1, partial; 0, none; 9, uncertain | Some response, decrease; Complete response, 0; No response, non-decreasing | Number of cells in 1/4 HPF (average of 3 fields) |
Decidual change | 1, partial; 0, none; 9, uncertain | Partial response, absent to present; No response, present to absent or present to present | Absent; Present |
References
- Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA A Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [CrossRef] [PubMed]
- Morice, P.; Leary, A.; Creutzberg, C.; Abu-Rustum, N.; Darai, E. Endometrial cancer. Lancet 2016, 387, 1094–1108. [Google Scholar] [CrossRef]
- Dizon, D.S.; Birrer, M.J. Advances in the diagnosis and treatment of uterine sarcomas. Discov. Med. 2014, 17, 339–345. [Google Scholar] [PubMed]
- Wan, Y.L.; Beverley-Stevenson, R.; Carlisle, D.; Clarke, S.; Edmondson, R.J.; Glover, S.; Holland, J.; Hughes, C.; Kitchener, H.C.; Kitson, S.; et al. Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions. Gynecol. Oncol. 2016, 143, 287–293. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez, A.C.; Blanchard, Z.; Maurer, K.A.; Gertz, J. Estrogen Signaling in Endometrial Cancer: A Key Oncogenic Pathway with Several Open Questions. Horm. Cancer 2019, 10, 51–63. [Google Scholar] [CrossRef]
- Zaino, R.J.; Brady, W.E.; Todd, W.; Leslie, K.; Fischer, E.G.; Horowitz, N.S.; Mannel, R.S.; Walker, J.L.; Ivanovic, M.; Duska, L.R. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: A Gynecologic Oncology Group study. Int. J. Gynecol. Pathol. 2014, 33, 543–553. [Google Scholar] [CrossRef]
- Duska, L.R.; Filiaci, V.L.; Walker, J.L.; Holman, L.L.; Hill, E.K.; Moore, R.G.; Ring, K.L.; Pearl, M.L.; Muller, C.Y.; Kushnir, C.L.; et al. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2021, 27, 2734–2741. [Google Scholar] [CrossRef]
- Wen, W.; Lowe, G.; Roberts, C.M.; Finlay, J.; Han, E.S.; Glackin, C.A.; Dellinger, T.H. Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancer. Sci. Rep. 2017, 7, 12754. [Google Scholar] [CrossRef]
- Kapetanovic, I.M.; Muzzio, M.; Huang, Z.; Thompson, T.N.; McCormick, D.L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 2011, 68, 593–601. [Google Scholar] [CrossRef]
- McCormack, D.; McFadden, D. A review of pterostilbene antioxidant activity and disease modification. Oxid. Med. Cell Longev. 2013, 2013, 575482. [Google Scholar] [CrossRef]
- Koh, Y.C.; Lin, S.J.; Hsu, K.Y.; Nagabhushanam, K.; Ho, C.T.; Pan, M.H. Pterostilbene Enhances Thermogenesis and Mitochondrial Biogenesis by Activating the SIRT1/PGC-1α/SIRT3 Pathway to Prevent Western Diet-Induced Obesity. Mol. Nutr. Food Res. 2023, 67, e2300370. [Google Scholar] [CrossRef]
- Alosi, J.A.; McDonald, D.E.; Schneider, J.S.; Privette, A.R.; McFadden, D.W. Pterostilbene inhibits breast cancer in vitro through mitochondrial depolarization and induction of caspase-dependent apoptosis. J. Surg. Res. 2010, 161, 195–201. [Google Scholar] [CrossRef] [PubMed]
- Mannal, P.; McDonald, D.; McFadden, D. Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro. Am. J. Surg. 2010, 200, 577–580. [Google Scholar] [CrossRef]
- Pan, M.H.; Chang, Y.H.; Badmaev, V.; Nagabhushanam, K.; Ho, C.T. Pterostilbene induces apoptosis and cell cycle arrest in human gastric carcinoma cells. J. Agric. Food Chem. 2007, 55, 7777–7785. [Google Scholar] [CrossRef]
- Suh, N.; Paul, S.; Hao, X.; Simi, B.; Xiao, H.; Rimando, A.M.; Reddy, B.S. Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13, 350–355. [Google Scholar] [CrossRef] [PubMed]
- Kostin, S.F.; McDonald, D.E.; McFadden, D.W. Inhibitory effects of (−)-epigallocatechin-3-gallate and pterostilbene on pancreatic cancer growth in vitro. J. Surg. Res. 2012, 177, 255–262. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.L.; Shen, Y.; Xu, J.P.; Han, K.; Zhou, Y.; Yang, S.; Yin, J.Y.; Min, D.L.; Hu, H.Y. Pterostilbene suppresses human endometrial cancer cells in vitro by down-regulating miR-663b. Acta Pharmacol. Sin. 2017, 38, 1394–1400. [Google Scholar] [CrossRef]
- Kim, K.-J.; Seo, Y.-J.; Koh, E.-J.; Choi, J.; Hwang, J.-H.; Lee, Y.-J.; Song, J.-H.; Chei, S.; Choi, S.-Y.; Park, M.-K.; et al. Pterostilbene inhibits adipocyte differentiation by targeting CHOP10 in 3T3-L1. FASEB J. 2017, 31, 646.43. [Google Scholar] [CrossRef]
- Hsiao, P.C.; Chou, Y.E.; Tan, P.; Lee, W.J.; Yang, S.F.; Chow, J.M.; Chen, H.Y.; Lin, C.H.; Lee, L.M.; Chien, M.H. Pterostilbene simultaneously induced G0/G1-phase arrest and MAPK-mediated mitochondrial-derived apoptosis in human acute myeloid leukemia cell lines. PLoS ONE 2014, 9, e105342. [Google Scholar] [CrossRef]
- Tang, D.; Xiao, W.; Gu, W.-T.; Zhang, Z.-T.; Xu, S.-H.; Chen, Z.-Q.; Xu, Y.-H.; Zhang, L.-Y.; Wang, S.-M.; Nie, H. Pterostilbene prevents methylglyoxal-induced cytotoxicity in endothelial cells by regulating glyoxalase, oxidative stress and apoptosis. Food Chem. Toxicol. 2021, 153, 112244. [Google Scholar] [CrossRef]
- Wen, W.; Lowe, G.; Roberts, C.M.; Finlay, J.; Han, E.S.; Glackin, C.A.; Dellinger, T.H. Pterostilbene Suppresses Ovarian Cancer Growth via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the STAT3 Pathway. Int. J. Mol. Sci. 2018, 19, 1983. [Google Scholar] [CrossRef] [PubMed]
- Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 2014, 30, 2114–2120. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.; Zhou, Y.; Chen, Y.; Gu, J. fastp: An ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 2018, 34, i884–i890. [Google Scholar] [CrossRef] [PubMed]
- Dobin, A.; Davis, C.A.; Schlesinger, F.; Drenkow, J.; Zaleski, C.; Jha, S.; Batut, P.; Chaisson, M.; Gingeras, T.R. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 2013, 29, 15–21. [Google Scholar] [CrossRef] [PubMed]
- Liao, Y.; Smyth, G.K.; Shi, W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019, 47, e47. [Google Scholar] [CrossRef]
- Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140. [Google Scholar] [CrossRef]
- Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015, 43, e47. [Google Scholar] [CrossRef]
- Mootha, V.K.; Lindgren, C.M.; Eriksson, K.F.; Subramanian, A.; Sihag, S.; Lehar, J.; Puigserver, P.; Carlsson, E.; Ridderstråle, M.; Laurila, E.; et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34, 267–273. [Google Scholar] [CrossRef]
- Bruno, F.; Naselli, F.; Brancato, D.; Volpes, S.; Cardinale, P.S.; Saccone, S.; Federico, C.; Caradonna, F. Effects of Pterostilbene on the Cell Division Cycle of a Neuroblastoma Cell Line. Nutrients 2024, 16, 4152. [Google Scholar] [CrossRef]
- Mahmud, S.A.; Manlove, L.S.; Farrar, M.A. Interleukin-2 and STAT5 in regulatory T cell development and function. Jakstat 2013, 2, e23154. [Google Scholar] [CrossRef]
- Xiao, M.; Xu, J.; Wang, W.; Zhang, B.; Liu, J.; Li, J.; Xu, H.; Zhao, Y.; Yu, X.; Shi, S. Functional significance of cholesterol metabolism in cancer: From threat to treatment. Exp. Mol. Med. 2023, 55, 1982–1995. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Lee, K.; Liang, Y.; Qin, S.; Zhu, Y.; Liu, J.; Yao, S. A Cholesterol Homeostasis-Related Gene Signature Predicts Prognosis of Endometrial Cancer and Correlates with Immune Infiltration. Front. Genet. 2021, 12, 763537. [Google Scholar] [CrossRef] [PubMed]
- Yang, Q.; Li, H.; Li, Z.; Yang, J.; Zhang, Z.; Zhang, L.; Guo, H.; Wei, W. Pterostilbene, an active constituent of blueberries, enhances innate immune activation and restricts enterovirus D68 infection. Front. Immunol. 2023, 14, 1118933. [Google Scholar] [CrossRef] [PubMed]
Arm 1 (MA+PT) (n = 19) | Arm 2 (MA) (n = 18) | All Evaluable Patients (n = 37) | |
---|---|---|---|
Median Age (y), (IQR) | 61.3 (57.3–70.9) | 63.9 (56.7–71.5) | 61.9 (57.3–70.9) |
Race | |||
Asian | 0 (0.0%) | 4 (22.2%) | 4 (10.8%) |
Black | 0 (0.0%) | 2 (11.1%) | 2 (5.4%) |
Pac/Islander | 0 (0.0%) | 1 (5.6%) | 1 (2.7%) |
White | 17 (89.5%) | 10 (55.6%) | 27 (73.0%) |
Unknown/Not disclosed | 2 (10.5%) | 1 (5.6%) | 3 (8.1%) |
Ethnicity | |||
Hispanic or Latino | 8 (42.1%) | 6 (33.3%) | 14 (37.8%) |
Non-Hispanic or Latino | 11 (57.9%) | 12 (66.7%) | 23 (62.2%) |
ECOG | |||
0 | 8 (42.1%) | 8 (44.4%) | 16 (43.2%) |
1 | 11 (57.9%) | 10 (55.6%) | 21 (56.8%) |
Menopausal status | |||
Postmenopausal | 18 (94.7%) | 17 (94.4%) | 35 (94.6%) |
Premenopausal | 1 (5.3%) | 1 (5.6%) | 2 (5.4%) |
FIGO uterine (path) | |||
IA | 10 (52.6%) | 8 (44.4%) | 18 (48.6%) |
IB | 6 (31.6%) | 1 (5.6%) | 7 (18.9%) |
II | 1 (5.3%) | 4 (22.2%) | 5 (13.5%) |
IIIA | 1 (5.3%) | 2 (11.1%) | 3 (8.1%) |
IIIC1 | 0 (0.0%) | 1 (5.6%) | 1 (2.7%) |
IVB | 0 (0.0%) | 1 (5.6%) | 1 (2.7%) |
Unstaged | 1 (5.3%) | 0 (0.0%) | 1 (2.7%) |
Unknown/missing | 0 (0.0%) | 1 (5.6%) | 1 (2.7%) |
Path Histology | |||
Carcinosarcoma | 1 (5.3%) | 0 (0.0%) | 1 (2.7%) |
Endometrioid | 16 (84.2%) | 14 (77.8%) | 30 (81.1%) |
Endometrioid hyperplasia with atypia | 1 (5.3%) | 1 (5.6%) | 2 (5.4%) |
Mucinous | 0 (0.0%) | 1 (5.6%) | 1 (2.7%) |
Serous | 1 (5.3%) | 2 (11.1%) | 3 (8.1%) |
Pathologic grade | |||
1 | 10 (52.6%) | 8 (44.4%) | 18 (48.6%) |
2 | 6 (31.6%) | 7 (38.9%) | 13 (35.1%) |
3 | 3 (15.8%) | 2 (11.1%) | 5 (13.5%) |
NA | 0 (0.0%) | 1 (5.6%) | 1 (2.7%) |
Cytologic result | |||
Negative | 13 (68.4%) | 11 (61.1%) | 24 (64.9%) |
Not Applicable | 5 (26.3%) | 6 (33.3%) | 11 (29.7%) |
Positive | 1 (5.3%) | 1 (5.6%) | 2 (5.4%) |
No. pelvic nodes removed | |||
0 | 8 (42.1%) | 8 (44.4%) | 16 (43.2%) |
1–2 | 5 (26.3%) | 5 (27.8%) | 10 (27.0%) |
3–6 | 4 (21.1%) | 3 (16.7%) | 7 (18.9%) |
NA | 2 (10.5%) | 2 (11.1%) | 4 (10.8%) |
Lymphovascular invasion | |||
Absent | 16 (84.2%) | 11 (61.1%) | 27 (73.0%) |
Present | 3 (15.8%) | 6 (33.3%) | 9 (24.3%) |
NA | 0 (0.0%) | 1 (5.6%) | 1 (2.7%) |
Median Tumor size (cm), (IQR) | 3.7 (1.0–5.0) | 5.1 (3.0–7.3) | 4.2 (2.0–7.0) |
Median Treatment Duration (d), (IQR/Range) | 20 (16–22/14–56) | 21 (20–28/14–52) | 21 (18–27/14–56) |
<3 weeks | 10 (52.6%) | 8 (44.4%) | 18 (48.6%) |
≥3 weeks | 9 (47.4%) | 10 (55.6%) | 17 (52.4%) |
Arm 1 (PT+MA) N = 19 | Arm 2 (MA) N = 18 | Total N = 37 | ||||
---|---|---|---|---|---|---|
Adverse Event | Grade 2 | Grade 3 | Grade 2 | Grade 3 | Grade 2 | Grade 3 |
Constipation | 1 | 1 | ||||
Dizziness | 1 | 1 | ||||
Fatigue | 1 | 1 | ||||
Gait disturbance | 1 | 1 | ||||
Headache | 1 | 1 | ||||
Hypertension | 1 | 1 | ||||
Rash maculo-papular | 1 | 1 | ||||
Thromboembolic event | 1 | 1 | ||||
Urinary tract infection | 1 | 1 | ||||
Uterine pain | 1 | 1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Senguttuvan, R.N.; Cho, H.; Wu, X.; Frankel, P.H.; Ruel, N.; Yost, S.E.; Kebria, M.; Han, E.; Song, M.; de Leon, M.; et al. The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate. Antioxidants 2025, 14, 345. https://doi.org/10.3390/antiox14030345
Senguttuvan RN, Cho H, Wu X, Frankel PH, Ruel N, Yost SE, Kebria M, Han E, Song M, de Leon M, et al. The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate. Antioxidants. 2025; 14(3):345. https://doi.org/10.3390/antiox14030345
Chicago/Turabian StyleSenguttuvan, Rosemary N., Hyejin Cho, Xiwei Wu, Paul H. Frankel, Nora Ruel, Susan E. Yost, Mehdi Kebria, Ernest Han, Mihae Song, Maria de Leon, and et al. 2025. "The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate" Antioxidants 14, no. 3: 345. https://doi.org/10.3390/antiox14030345
APA StyleSenguttuvan, R. N., Cho, H., Wu, X., Frankel, P. H., Ruel, N., Yost, S. E., Kebria, M., Han, E., Song, M., de Leon, M., Invernizzi, M., Eng, M., Tinsley, R., Salehian, B., Li, A., Schmolze, D., Chang, S., Arias-Stella, J., & Dellinger, T. H. (2025). The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate. Antioxidants, 14(3), 345. https://doi.org/10.3390/antiox14030345